Brief: Novocure Ltd FDA Approves Optune Lua For Concurrent Use With Pd-1/Pd-L1 Inhibitors For Treatment Of Metastatic Non-Small Cell Lung Cancer

NovoCure

15/10/2024 21:15

Oct 15 (Reuters) - Novocure Ltd  NVCR.O :
    * NOVOCURE LTD: FDA APPROVES OPTUNE LUA FOR CONCURRENT USE
WITH
PD-1/PD-L1 INHIBITORS FOR TREATMENT OF METASTATIC NON-SMALL CELL
LUNG CANCER
    * NOVOCURE LTD: PRIMARY ENDPOINT OF STUDY WAS ACHIEVED

Source text for Eikon:  ID:n0001645113-24-000030 
Further company coverage:  NVCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))